MedTrace Logo

Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:

NCT05847088 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2023-05-06

No results posted yet for this study

Summary

We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing our results , evaluating both anatomical and functional outcomes of DEX therapy for refractory DME.

Conditions

Interventions

DRUG

Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:

Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.

Sponsors & Collaborators

  • Dar El Oyoun Hospital

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2023-03-28
Completion
2023-04-04

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847088 on ClinicalTrials.gov